Recommendation ID
NICE supports the manufacturer's ongoing commitment to collect data on the effectiveness of enzalutamide after previous treatment with abiraterone.
Any explanatory notes
(if applicable)
The use of enzalutamide for treating metastatic hormone-relapsed prostate cancer previously treated with abiraterone is not covered by this guidance.

Source guidance details

Comes from guidance
Enzalutamide for metastatic hormone‑relapsed prostate cancer previously treated with a docetaxel‑containing regimen
Date issued
July 2014

Other details

Is this a recommendation for the use of a technology only in the context of research? N/A  
Is it a recommendation that suggests collection of data or the establishment of a register?   N/A  
Last Reviewed 07/10/2014